GO
Loading...

Actavis Inc

More

  • Halliburton and Allergan are big market movers Monday, 17 Nov 2014 | 4:33 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Halliburton Co., down $5.85 to $49.23. The Botox maker is being bought by Actavis for $66 billion, which tops a bid made by Valeant Pharmaceuticals last spring.

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...

  • *Brent falls toward $78 as Japanese growth stalls. NEW YORK, Nov 17- Oil prices fell and global equity markets were mixed on Monday after news that Japan unexpectedly slipped into recession in the third quarter renewed concerns about the world economy, but merger activity and comment about European stimulus capped declines. Brent oil initially fell more than $1...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 10.2 percent, and Allergan, up 5.1 percent, led gains on the S&P 500 after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. The largest percentage gainer on the S&P 500 was Baker Hughes, while the largest decliner was Halliburton, down 10.1 percent.

  • NEW YORK, Nov 17- Actavis will issue around US $27.5 bn of new debt to finance its US $66 bn acquisition of Botox-maker Allergan, but about half of it will be short-dated to help the company keep its investment-grade ratings. Both Moody's and Fitch said they would not downgrade Actavis to junk despite the increased debt, believing strong cash flow will enable it to...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • NEW YORK, Nov 17- Hedge fund Omega Advisors expects to see the U.S. stock market's bull run continue into next year, fueled by steady economic growth and a corporate takeover boom. "My expectation is for the Standard& Poor's 500 to gain 7 percent to 9 percent in 2015," Steven Einhorn, Omega's vice chairman said on Monday. Omega, founded by Leon Cooperman two decades ago...

  • *Baker Hughes rallies, Halliburton tumbles after deal. The M&A news partly offset the declines as Allergan agreed to be bought by Actavis while Halliburton said it would buy Baker Hughes. Allergan and Baker Hughes were the top point gainers on the S&P 500..

  • *Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news offset the declines as Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis.

  • Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...

  • Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..

  • Actavis to spend $66 billion on Allergan Monday, 17 Nov 2014 | 9:32 AM ET

    Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.

  • NEW YORK— Pharmaceutical giant Actavis to buy Botox maker Allergan for $66 billion in cash-and-stock.

  • Allergan agrees to Actavis deal for $66 billion Monday, 17 Nov 2014 | 9:20 AM ET

    Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc. The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently...

  • *Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout by Actavis.

  • US STOCKS-Futures slip as Japan dips into recession Monday, 17 Nov 2014 | 7:42 AM ET

    *Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout deal by Actavis. *Baker Hughes rose 16.4 percent on news Halliburton would acquire it in a cash and stock transaction of about $34.6 billion. *Allergan added 4.5 percent as the Actavis buyout values the company as high as $65.5...

  • Ahead of the Bell: Allergan soars on deal reports Monday, 17 Nov 2014 | 7:38 AM ET

    Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the Botox maker, which is fighting off a separate takeover bid from Valeant Pharmaceuticals. The New York Times reported that Allergan is nearing a deal to sell itself to Actavis for more than $62.5...

  • Japan stocks rise on hopes for new stimulus Monday, 17 Nov 2014 | 1:58 AM ET

    The latest milestone for the S&P 500 came on a day when the major U.S. stock indexes mostly hovered between small gains and losses as investors weighed the implications of an economic slowdown in Japan that worsened in the third quarter into a recession. "Japan definitely started us on a bit of a negative tone with the economy back into recession," said Chris...

  • Nov 16- Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter. Actavis may pay Allergan between $215 and $220 per share, with the final price likely...

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...